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Abstract
Macrophage CSF (M-CSF) regulates monocyte differentiation, activation, and foam cell formation.
We have observed that it is elevated in human pulmonary alveolar proteinosis (PAP) and in the GM-
CSF knockout mouse, a murine model for PAP. A potential regulator of M-CSF, peroxisome
proliferator-activated receptor-γ (PPARγ), is severely deficient in both human PAP and the GM-CSF
knockout mouse. To investigate the role of PPARγ in alveolar macrophage homeostasis, we
generated myeloidspecific PPARγ knockout mice using the Lys-Cre method to knock out the floxed
PPARγ gene. Similar to the GM-CSF-deficient mouse, absence of alveolar macrophage PPARγ
resulted in development of lung pathology resembling PAP in 16-wk-old mice, along with excess
M-CSF gene expression and secretion. In ex vivo wild-type alveolar macrophages, we observed that
M-CSF itself is capable of inducing foam cell formation similar to that seen in PAP. Overexpression
of PPARγ prevented LPS-stimulated M-CSF production in RAW 264.7 cells, an effect that was
abrogated by a specific PPARγ antagonist, GW9662. Use of proteasome inhibitor, MG-132 or a
PPARγ agonist, pioglitazone, prevented LPS-mediated M-CSF induction. Using chromatin
immunoprecipitation, we found that PPARγ is capable of regulating M-CSF through transrepression
of NF-κB binding at the promoter. Gel-shift assay experiments confirmed that pioglitazone is capable
of blocking NF-κB binding. Taken together, these data suggest that M-CSF is an important mediator
of alveolar macrophage homeostasis, and that transcriptional control of M-CSF production is
regulated by NF-κB and PPARγ.
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Peroxisome proliferator-activated receptor-γ (PPARγ)2 is a member of the ligand-activated
nuclear hormone receptor family that can function as a transcription factor (1). PPARs have
been reported in the regulation of genes involved in lipid and glucose metabolism as well as
inflammation (2,3). Although weakly expressed in monocytes, PPARγ is up-regulated during
differentiation into macrophages and is predominantly nuclear in location (4). Our studies are
the first to describe the constitutive expression of PPARγ in healthy human alveolar
macrophages and the striking deficiency of PPARγ in pulmonary alveolar proteinosis (PAP).
Alveolar proteinosis is an autoimmune disease in which neutralizing autoantibodies to GM-
CSF result in a deficiency of bioactive GM-CSF in the lung (5). Intraalveolar accumulation of
periodic acid-Schiff (PAS)-positive lipoproteinaceous material inhibits gas exchange in the
lungs of patients with PAP (6). The deficiency of PPARγ can be reversed in vitro by GM-CSF
and therapeutically in disease by treating with exogenous GM-CSF (7). Alveolar macrophages
obtained from the GM-CSF knockout (KO) mouse, the animal model of PAP, are also deficient
in PPARγ.
Monocytes recruited into the lungs are thought to mature into alveolar macrophages in a process
dependent upon GM-CSF (8,9). GM-CSF and macrophage CSF (M-CSF) are CSFs associated
with the regulation of myeloid differentiation (10–13). The lack of GM-CSF has been thought
to be a trigger for increased production of M-CSF as a compensatory mechanism, although
this issue remains incompletely defined (14,15). In support of this, we and others have observed
that both human PAP and the GM-CSF KO mice overproduce M-CSF (5,16). Furthermore,
therapeutic administration of biologically active GM-CSF restores PPARγ levels and decreases
M-CSF in human PAP (17,18).
GM-CSF has been implicated in the classical activation of macrophages resulting in the up-
regulation of MHC class II molecules and CD86, whereas M-CSF has been associated with
alternative macrophage activation (19). Alternative macrophage activation by M-CSF has been
linked to the induction of IL-10 and matrix metalloproteinases (19–21), both of which are
elevated in PAP (17,22). M-CSF has also been associated with enhanced foam cell formation
in vitro (23–25). These observations suggest that M-CSF may play a role in the accumulation
of lipids in PAP alveolar macrophages and in the GM-CSF KO model. We hypothesized that
deficient PPARγ results in the up-regulation of alveolar macrophage M-CSF, and excess M-
CSF contributes ultimately to the accumulation of foam cells. We demonstrate herein that
PPARγ can regulate M-CSF production through transrepression of NF-κB. Furthermore,
because GM-CSF is required for alveolar macrophage PPARγ expression, these data link the
absence of GM-CSF with the accumulation of M-CSF in alveolar proteinosis.
Materials and Methods
Mice
Conditional PPARγ KO mice—Homozygous floxed (+/+) PPARγ mice were generously
provided by Dr. F. J. Gonzalez (26). To achieve loss of PPARγ in macrophages, homozygous
floxed PPARγ mice were crossed into a transgenic mouse containing the CRE gene under the
control of the murine M lysozyme promoter (27). CRE-M lysozyme (+/+) mice were obtained
from the Jackson Laboratory. Thus, control mice for these experiments consist of: floxed (+/
+), CRE (−/−) mice (1) and floxed (−/−), CRE (+/+) mice (2).
2Abbreviations used in this paper: PPARγ, peroxisome proliferator-activated receptor-γ; BAL, bronchoalveolar lavage; ChIP, chromatin
immunoprecipitation; KO, knockout; M-CSF, macrophage CSF; PAS, periodic acid-Schiff; PAP, pulmonary alveolar proteinosis; PPRE,
peroxisome proliferator response element.
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GM-CSF KO mice—This mouse strain was generated by G. Dranoff et al. (28). The mice
have been backcrossed eight generations to C57BL/6. C57BL/6 wild-type mice obtained from
The Jackson Laboratory were used as controls.
Murine cell source
Alveolar macrophages—Mice were injected subcutaneously with a lethal dose of ketamine
(80 mg/kg) and xylazine (10 mg/kg). Bronchoalveolar lavage (BAL) was performed by
inserting a cannula through a cut in the trachea into the bronchi and infusing 10 × 1-ml aliquots
of warm PBS containing 0.2% lidocaine. The BAL fluid sample is recovered by aspirating the
liquid with a syringe; we recovered 80 ± 23% of instilled fluid volume. Macrophages were
harvested and cultured overnight before experimentation.
Resident peritoneal macrophages—Mice were injected with a lethal dose of ketamine
and xylazine and cells recovered by lavage. Macrophages were harvested and cultured
overnight before experimentation.
Bone marrow-derived macrophages—BALB/c mice were used for bone marrow-
derived macrophage studies. The femur and tibia were removed and wiped with a sterile alcohol
tissue (29,30). The bones were then put into RPMI containing antibiotics and, using a sterile
1 cc syringe, fresh RPMI was pushed through the bone marrow cavity. The bone marrow cells
were counted with differentials and viability stains, followed by culture for 6–7 days with L929
support medium.
Lung pathology—Animal models and age-matched controls were euthanized; lungs were
snap frozen for lipid stains.
Human BAL-derived macrophages
Alveolar macrophages were derived from BAL obtained by flexible bronchoscopy as
previously described (31). Differential cell counts were obtained from cytospins stained with
a modified Wright's stain. All differential cell counts represented at least 200 cells. Mean
viability of lavage cells was >95% by trypan blue dye exclusion.
Histological staining
Alveolar, bone marrow-derived, and peritoneal macrophages were isolated from 4 – 6-wk-old
mice. Macrophages were stained with Oil-Red-O for neutral lipids (27,32). Alveolar
macrophages from 6-wk GM-CSF KO were used as positive controls. Cells were fixed for 5
min in 1% paraformaldehyde in PBS. A stock solution of Oil-Red-O was diluted in methanol
and filtered. Cells were incubated for 30 min in Oil-Red-O staining solution and then destained
in 100% methanol for 5 min. The number of cells staining red in 10 high power fields (×40)
was determined and expressed as percentage Oil-Red-O positive.
Cell culture conditions
Cells were cultured in 6-well, 12-well, or 24-well plates, depending on the experiment, at
consistent cell densities. Primary cells were allowed to adjust to culture overnight before the
addition of stimuli: LPS (50 –500 ng/ml), M-CSF (100 ng/ml), irreversible PPARγ antagonist
GW9662 (10 μM; Sigma-Aldrich), and/or PPARγ agonist pioglitazone (10 μM, Takeda
Chemical Industries). A proteasome inhibitor, 6-amino-4-(4-phenoxyphenylethylamino)
quinazoline (Calbiochem), was used to block NF-κB activation. Cells were harvested for either
extracts for protein-DNA interactions, activated transcription factors, or mRNA analysis.
Supernatants were harvested for secreted M-CSF.
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Transfection experiments
PPARγ expression vector was generously supplied by Todd Leff (Wayne State University).
Two micrograms of CMV-β-gal (Jahar Haque, Cleveland Clinic Foundation) or pTR100
expression vector was transfected into 2 × 106 RAW 264.7 cells in a 6-well plate using calcium
phosphate precipitation method as previously described (33) Transfection efficiency was
verified with cotransfection with GFP expression vector (Invitrogen).
RNA purification and analysis
Bone marrow, peritoneal, and alveolar macrophages from GM-CSF and PPARγ KO mice were
cultured for 24 h in OptiMEM (Life Technologies/Invitrogen) before incubation with or
without M-CSF stimulants (PMA, TNF), with concentration and duration being as prescribed
by the initial experiment. Total RNA was extracted by RNAeasy protocol (Qiagen). Expression
of mRNA was determined by real time RT-PCR as previously described (7).
M-CSF protein
Murine and human ELISA assays were done according to manufacturers specifications
(BioSource International).
Electophorectic mobility shift assay
The assay was performed as previously described (34). In brief, RAW 264.7 cells were cultured
with LPS (50 ng/ml) or pioglitazone (10 μM) for 3 h. Supershifts were performed with anti-
p65 and anti-p50 (Santa Cruz Biotechnology) added before the addition of the probe. The
specificity of the probe was shown by incubating the extract with a 1000-fold molar excess of
cold oligonucleotide. StormImager (Molecular Dynamics) and ImageQuant software were
used for quantification of autoradiographs. The sequence of the NF-κB binding site was 5′-
AACTCCGGGAATTTCCCTGGCCC-3′.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed following the instructions of the ChIP assay kit (Upstate
Biotechnology) and the protocol outlined previously (29,35–38). Briefly, using the reagents
provided in the chromatin precipitation kit, we immunoprecipitated protein-DNA complex Abs
specific for PPARγ (sc-7273, Santa Cruz Biotechnology), p65 (sc-8008), or p50 (sc-114)) after
bone marrow-derived macrophages were cultured in the presence and absence of pioglitazone
(10 μM), LPS (500 ng/ml), or GW9662 (5 μM). Input DNA was normalized by OD (39). The
presence of associated PPARγ, p65, or c-Rel was measured by real-time PCR with the ABI
Prism 7700 sequence detection system using SYBR Green PCR reagents (Applied
Biosystems). PCR was done with nested primers to ensure specificity, and agarose gel analyses
were performed after PCR amplification to ensure that a single product with expected size was
amplified. The M-CSF promoter (40–44), peroxisome proliferator response element (PPRE),
and NF-κB primers are shown in Table I.
Statistical analysis
Analysis was performed using Prism GraphPad software version 3.0. Comparisons were
performed using Student's t test or Mann-Whitney U test, as appropriate. For multiple
comparisons, repeated measures ANOVA and Dunnett's test were used.
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Results
Alveolar macrophage phenotype is similar in PPARγ KO and GM-CSF KO mice
To determine the impact of the PPARγ deficiency on PAP-like lung disease, we compared lung
histopathology from 16-wk-old PPARγ and GM-CSF KO mice after staining with PAS (Fig.
1). The GM-CSF KO mice were positive for PAS as previously reported (Fig. 1A) (15,28).
Accumulated PAS-positive material was abundant in alveolar spaces in two out of seven
PPARγ KO mice, with one exhibiting robust intraalveolar PAS staining (Fig. 1B). PPARγ KO
mice at 6 wk did not have significant pathology (not shown). This suggests that intraalveolar
accumulation occurs slowly as disease progresses. However, all PPARγ KO mice had abundant
PAS staining in the alveolar macrophages (Fig. 1B, inset). The BAL total and differential cell
counts are displayed in Table II (n = 5 per condition). These data suggest that there are
significantly more cells in the GM-CSF KO mice (mean ± SD of 6.9 ± 4.9 × 104 cells/ml) than
in wild-type controls (1.3 ± 0.3 × 104 cells/ml, p = 0.04). There was a trend (p = 0.07) toward
more cells in the PPARγ KO mice as well (2.9 ± 1.7 × 104 cells/ml) vs the wild-type mice.
Although macrophages were the most abundant cell type in all models, there were increased
numbers of lymphocytes in both the GM-CSF KO and PPARγ KO mice, and relative BAL
neutrophilia as well in the PPARγ KO mice. Observations in the GM-CSF KO mice are
consistent with the literature (45).
Exogenous M-CSF is capable of inducing PAP-like surfactant uptake in alveolar
macrophages
Because M-CSF has been associated with foam cell formation (46,47), and we previously
observed elevations of M-CSF in the setting of GM-CSF deficiency (5), we hypothesized that
M-CSF overproduction contributes to the lipid-cell phenotype observed in the PPARγ and GM-
CSF KO models. Alveolar macrophages from C57BL/6 mice were cultured in Lab-Tek
chambers in the presence and absence of murine M-CSF (100 ng/ml) or human PAP surfactant
material (200 ng/ml) (Fig. 2). The percentage of positive staining cells for each condition is
depicted in Fig. 2E. Surfactant alone (p = 0.001) or M-CSF alone (p = 0.008) induced greater
numbers of Oil-Red-O-positive alveolar macrophages than control cells. However, the
combination of surfactant and M-CSF induced significantly greater uptake than either
condition alone (p = 0.03 for the comparison of M-CSF alone or surfactant alone vs M-CSF +
surfactant). Antibody-induced neutralization of M-CSF reversed the effects of exogenous M-
CSF on lipid processing but did not alter the effects of surfactant alone on induction of Oil-
Red-O-positive cells.
M-CSF is elevated in both the GM-CSF KO and macrophage-specific PPARγ KO mice
We have previously reported that PPARγ is deficient in human PAP (48). We have also shown
that PPARγ is deficient in the GM-CSF KO alveolar macrophages (49). To determine whether
these two models also demonstrated similarities in M-CSF expression, we collected BAL cells
and fluid from both KO genotypes. Gene expression was assessed using fresh whole cells,
because most are alveolar macrophages (Table II). Fig. 3 demonstrates that both GM-CSF and
PPARγ KO mice have increased M-CSF gene expression and protein levels compared with
controls (n = 4–5 for all conditions, p ≤ 0.002 vs wild type mice). The elevation of M-CSF was
specific for alveolar macrophages and the lung milieu because peritoneal macrophages did not
express elevated levels of M-CSF mRNA or M-CSF protein in the peritoneal fluid compared
with controls, regardless of whether the cells were elicited by thioglycollate or not (data not
shown).
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PPARγ overexpression inhibits M-CSF production
RAW 264.7 cells were transfected with 2 μg/ml PPARγ expression vector. We measured the
expression of M-CSF after 24 h with and without LPS stimulation. The transfection resulted
in 10,809 ± 1578% increase in PPARγ expression (Fig. 4, p ≤ 0.001, n = 3). Expression of
PPARγ after transfection was not affected by the addition of LPS (p = 0.98). Constitutive
expression of M-CSF in RAW cells was decreased to 31 ± 4% of control levels (CMV β-gal
vector) by transfection with a PPARγ expression vector. In the presence of LPS, M-CSF
expression was induced by 20 ± 1.2-fold vs control (n = 3, p = 0.02). LPS-induced M-CSF
production was inhibited by overexpression of PPARγ (10.9 ± 13.2% of LPS alone, p = 0.017,
n = 3). In additional experiments, RAW cells were cultured in the presence and absence of a
specific PPARγ agonist, pioglitazone, or an irreversible antagonist, GW9662. Pioglitazone
repressed the expected induction of M-CSF transcription by 41 ± 6% percent (Fig. 5A, p =
0.04). Conversely, baseline RAW cells treated with GW9662 spontaneously increased their
M-CSF gene expression by 532 ± 241% (Fig. 5B, p = 0.02), suggesting that basal PPARγ
activity maintains repression of the M-CSF promoter, even in the absence of inflammatory
stimuli. To assess the generalizability of these findings, we repeated the experiments using
bone marrow-derived macrophages. LPS stimulated bone marrow-derived macrophages (n =
4) had a 21 ± 0.5-fold increase in M-CSF mRNA gene expression, which was decreased to 2.2
± 0.1 (p = 0.001) with pioglitazone. Treatment of the bone marrow macrophages with GW9662
resulted in a 57 ± 1.7-fold increase in M-CSF mRNA expression (p ≤ 0.001). Because previous
studies have shown that alveolar macrophages from PAP patients express high levels of M-
CSF (17), healthy control alveolar macrophages were cultured in the presence and absence of
either pioglitazone or PPARγ agonists/antagonists to determine whether the impact of
PPARγ agonists/antagonists would be the same on M-CSF production. Similar to the RAW
cells and the bone marrow-derived macrophages, healthy control alveolar macrophages treated
with GW9662 secreted 12 ± 2% more M-CSF than did cultured controls (p = 0.04). LPS-
stimulated alveolar macrophage M-CSF production was decreased by 30 ± 12% with the
addition of pioglitazone (n = 3, p = 0.02). The observed modest change in M-CSF protein
production compared with mRNA expression may be due to the release of preformed M-CSF,
enhanced M-CSF stability relative to M-CSF protein, and/or preferential production of
membrane-bound M-CSF. This is the subject of ongoing studies.
PPARγ regulates M-CSF through NF-κB
Analysis of the M-CSF promoter, as well as prior reports, suggested that NF-κB is crucial for
constitutive and inducible gene expression (50). To determine whether PPARγ binding to the
NF-κB site affected M-CSF transcription, experiments were designed to measure M-CSF
transcription in the presence and absence of a proteasome inhibitor, 6-amino-4-(4-
phenoxyphenylethylamino) quinazoline, which prevents activation of NF-κB by blocking
IκBα degradation. RAW 264.7 cells were stimulated for 6 h with LPS, resulting in 21.6 ± 0.9-
fold increase in M-CSF expression (Fig. 6, n = 4 for each condition). LPS-induced M-CSF
expression was reduced by 60 ± 26% when NF-κB activation was inhibited. Pioglitazone
treatment also decreased LPS-stimulated M-CSF expression, by 68 ± 15% compared with the
LPS control (p < 0.05). The combination of both pioglitazone and NF-κB inhibition resulted
in a further reduction of M-CSF expression, to 19.7 ± 25% of LPS alone (p < 0.001 vs LPS).
These data suggest that PPARγ regulates M-CSF production through repression of NF-κB.
PPARγ regulation of M-CSF did not appear to involve MAPK pathways because ERK inhibitor
(PD 98059) and p38 inhibitor (SB 203580) did not alter M-CSF gene expression (data not
shown).
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Pioglitazone inhibits NF-κB activation
Pioglitazone, a PPARγ agonist, has previously been shown to decrease activity of NF-κB-
regulated gene promoters in transient transfection assays (51). To confirm that this effect is
mediated by inhibition of NF-κB binding to DNA, we performed EMSAs using RAW 264.7
cells cultured for 3 h in the presence of LPS, pioglitazone, or pretreated with pioglitazone for
30 min before the addition of LPS. The extent of NF-κB DNA binding was quantified by
measuring radioactivity with phosphorimaging. Constitutive NF-κB binding was low and was
not significantly affected by pioglitazone alone (Fig. 7). After pretreatment with pioglitazone,
LPS-induced formation of NF-κB-DNA-binding complexes was reduced by 30.6 ± 6.9% (n =
4, p < 0.01 by Tukey's test).
PPARγ binds to NF-κB site and PPRE site upstream of the M-CSF promoter
To assess whether PPARγ could inhibit NF-κB transactivation of the M-CSF promoter, we
used bone marrow-derived macrophages for ChIP experiments. BALB/c bone marrow cells
were differentiated into macrophages using L929-supplemented medium. Cells were harvested
and cultured for 7 days before experiments. Bone marrow-derived macrophages were then
treated with LPS (500 ng/ml) or pioglitazone (10 μM). Cell lysates were immunoprecipitated
with anti-PPARγ, anti-p65, and anti c-Rel. Binding to the M-CSF promoter was determined
by real-time PCR. Positive MCSF promoter PCR reactions in the different immunoprecipitated
reactions reflect transcription factor association with the M-CSF promoter. As expected, LPS
resulted in p65 and c-Rel association with the NF-κB site (Fig. 8B). Activation of PPARγ by
pioglitazone enhanced PPARγ association with the same region (Fig. 8A, n = 2), while LPS
nearly abrogated PPARγ binding to the promoter. These data suggest that activation of
PPARγ is capable of repressing inflammatory signaling that can activate transcription at the
M-CSF promoter. The impact of PPARγ association with a PPRE site in the M-CSF promoter
is unknown at this time (Fig. 8C).
Discussion
GM-CSF is essential for alveolar macrophage differentiation and surfactant catabolism (7).
The mechanism whereby deficiency of bioactive GM-CSF induces accumulation of surfactant
material in human PAP and the GM-CSF KO model has not been delineated to date. Our data
suggest that the effect of GM-CSF deficiency to enhance M-CSF expression may be an
important clue about its role. The dysregulation of M-CSF appears to be due to deficiency of
PPARγ and is capable in vitro of inducing lipid accumulation in alveolar macrophages. In
support of this general concept, both the macrophage-specific PPARγ KO mode and the GM-
CSF KO mouse have similar accumulation of PAS-positive lipid material in the intraalveolar
space and alveolar macrophages. Cells harvested from the peritoneum did not demonstrate this
morphology, suggesting a mechanism unique to the alveolar microenvironment.
Additionally, the data presented herein demonstrate that M-CSF production in alveolar
macrophages can be regulated by PPARγ. Using chromatin immunoprecipitation, PPARγ
expression vectors and inhibitors for NF-κB, ERK, and JNK, we provide evidence that
PPARγ regulates M-CSF through transrepression of NF-κB activity. It is possible that the
effects of pioglitazone and the NF-κB inhibition involve unique or independent mechanisms.
The present report does not fully resolve this issue. We think it is likely, however, that the
repressive effect of PPARγ activation is mediated by blockade of NF-κB association with the
promoter. Data in support of this hypothesis include the EMSA analysis and the very robust
association of PPARγ with the NF-κB response element. The magnitude of reduction of
NFκB binding in the EMSA is almost identical to previously reported effects of pioglitazone
on LPS induction of NFκB-luciferase in RAW cells (51). Taken together, these results suggest
that the effects of pioglitazone are mediated by prevention of NFκB transactivation of the
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promoter. This mechanism is congruent with the model proposed for regulation of NF-κB
induction of the murine iNOS promoter in RAW cells (52–55).
Normally, production of M-CSF is low, a phenomenon that is partly due to basal repression
of the M-CSF promoter by PPARγ. In the presence of inflammatory signaling via NF-κB, up-
regulated M-CSF promoter activity can be modulated by PPARγ. These observations are
consistent with the PPARγ corepression mechanism suggested by Pascual et al. (52). From
these observations, we propose the model depicted in Fig. 9, showing that in the absence of
activation a corepressor complex may block M-CSF promoter activity. When PPARγ is
activated it binds to and stabilizes the corepressor, preventing accumulation of coactivator
proteins and NF-κB transactivation of the promoter, which requires degradation of the
corepressor complex. In the absence of PPARγ, constitutively low-level NF-κB binding at the
promoter allows basal MCSF production.
M-CSF is a CSF associated with the maturation, differentiation and survival of monocyte/
macrophages (10,41). During early myeloid differentiation, M-CSF alone cannot support the
proliferation and differentiation of multipotent progenitor cells; however, it synergizes with
other growth factors such as stem cell factor (also known as kit ligand) and IL-3 to produce
mononuclear phagocyte progenitor cells (56). After this initial differentiation process, MCSF
itself can regulate the proliferation and differentiation of mononucelar phagocyte progenitor
cells to monocytes and macrophages in addition to the survival, proliferation, and function of
fully differentiated macrophages. Additionally, M-CSF synergizes with receptor activator of
NF-κB ligand (RANKL) to regulate the differentiation of mononuclear phagocytes to
osteoclasts. Studies have shown that M-CSF induced bone-resorbing osteoclasts can be
inhibited by PPARγ ligands (57), which are congruent with our observations associating M-
CSF repression with PPARγ activation.
Overabundance of M-CSF can also lead to the development of disease. M-CSF-associated
enhancement of atherosclerosis is thought to be mediated by a local production of M-CSF
leading to the accumulation of cholesterol-filled foam cells in atherosclerotic plaques (56). In
obesity, the ratio of M-CSF-dependent macrophages to adipocytes in adipose tissue is
positively correlated with both adipocyte size and body mass (23). These and other studies
suggest that macrophages have an active role in morbid obesity and that macrophage-based
inflammatory activity supported by locally produced M-CSF might contribute to the
pathogenesis of obesity-induced insulin resistance (58). M-CSF also has a role in some
inflammatory diseases. The administration of Abs to M-CSF in the collagen-induced arthritis
model results in reduced severity of arthritis in mice, and M-CSF-deficient mice show a
decrease in recruitment, proliferation, and activation of macrophages in models of
inflammation (58,59). Our data suggest therefore that PPARγ has the potential to alter
monocyte/macrophage activation through the regulation of M-CSF, independent of GM-CSF.
This mechanism explains the observation that there is constitutive hyperproduction of M-CSF
in the GM-CSF KO mouse, because PPARγ is markedly deficient.
GM-CSF is essential for alveolar macrophage differentiation, surfactant catabolism, and
PPARγ expression (14,31,48,60). One of the implications of loss of GM-CSF-induced
PPARγ expression is on the production of M-CSF. These studies are the first to directly link
PPARγ to M-CSF production. M-CSF is essential in the survival, proliferation, and activation
of monocyte/macrophages. The PPARγ KO expresses normal levels of GM-CSF mRNA, but
also has elevated levels of M-CSF. This suggests that in any scenario in which PPARγ becomes
deficient or significantly decreased such as in inflammation, a switch turns on in which
macrophages may become alternatively activated potentially through the production of M-
CSF. The nature and phenotype of alveolar macrophage activation ultimately defines the
adaptive and innate immunity of the response to the insulting stimulus. These studies therefore
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are the first to directly associate PPARγ to alveolar macrophage M-CSF production and
potential activation and regulation of pulmonary immunity.
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FIGURE 1.
PPARγ knockout alveolar macrophage Pathology resembles the GM-CSF KO model. GM-
CSF KO (A), PPARγ KO (B), and C57BL/6 control (C) mice were sacrificed, and the lungs
stained with periodic-acid Schiff (×40). The GM-CSF KO model demonstrates scattered foci
of intraalveolar PAS-positive material (thick arrows, A) and lipid-engorged alveolar
macrophages (thick arrow, ×100 inset). All of the PPARγ KO mice (7 of 7 mice) exhibited
similar PAS-positive material in alveolar macrophages (B, ×100 inset). Similar to the GM-CSF
KO animals, several of these mice (2 of 7) also developed intraalveolar PAS-positive material
(B, thin arrow).
Bonfield et al. Page 13
J Immunol. Author manuscript; available in PMC 2010 February 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 2.
M-CSF induces alveolar macrophages to take up surfactant. Alveolar macrophages were
obtained from C57BL/6 mice and cultured in vitro with 200 ng/ml surfactant obtained from a
PAP patient in the presence and absence of human recombinant M-CSF. Figures depict ×40
images, representative of six independent experiments. Both surfactant (p = 0.001 vs controls)
and M-CSF (p = 0.008) induced Oil-Red-O-positive cells. Alveolar macrophages incubated
with surfactant and M-CSF had a cumulatively greater uptake of Oil-Red-O staining lipids
compared with either condition alone (p = 0.03 vs either). Each condition was evaluated for
(and counted in 6 frames of at least 200 cells) by blinded numerical designation. Data represent
mean percentage of positive Oil-Red-O staining ± SEM (n = 6). Abs to M-CSF neutralized the
effect of M-CSF on surfactant uptake to levels comparable to surfactant alone. US,
Unstimulated; S, surfactant.
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FIGURE 3.
M-CSF gene expression and protein are elevated in BAL specimens from GM-CSF and
PPARγ KO mice. Acellular BAL fluid was assessed for M-CSF protein by ELISA, and BAL
cell pellets were evaluated for M-CSF mRNA. Compared with wild-type mice (n = 5), BAL
cells from both GMCSF KO (n = 4) and PPARγ KO (n = 4) mice demonstrated increased M-
CSF gene expression (p ≤ 0.002 for each comparison, B). Similarly, BAL protein levels were
increased in both models when compared with wild-type mice (B, p < 0.002, n = 4 per
condition).
Bonfield et al. Page 15
J Immunol. Author manuscript; available in PMC 2010 February 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 4.
Transfection of PPARγ expression vector into RAW 264.7 cells attenuates LPS-mediated
induction of M-CSF. RAW 264.7 cells were transfected with 1 μg PPARγ murine expression
vector. We measured the expression of M-CSF after 24 h in the presence and absence of LPS.
Transient transfection of the PPARγ expression vector resulted in 10,809 ± 1,578% (mean ±
SEM) increased expression of PPARγ mRNA expression compared with the control (β-gal)
vector (right bars, n = 3, p ≤ 0.001). Compared with transfected controls (β-gal), LPS-induced
M-CSF production was inhibited by 90.1 ± 13.2% with the overexpression of PPARγ
expression vector (left bars, p = 0.017, n = 3).
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FIGURE 5.
M-CSF secretion is enhanced by PPARγ antagonists and suppressed by PPARγ agonist. RAW
cells were cultured in the presence and absence of pioglitazone or GW9662 at baseline or after
stimulation with LPS. LPS-stimulated RAW cells treated with pioglitazone expressed 41 ± 6%
significantly less M-CSF mRNA (A, p = 0.04, n = 4) and 12 ± 0.7% less M-CSF protein (p =
0.01) compared with the LPS cultures alone. Conversely, baseline RAW cells treated with
GW9662 increased their M-CSF gene expression and protein by 532 ± 242% (B, p = 0.02, n
= 3) and 11.2 ± 1% (p = 0.03), respectively.
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FIGURE 6.
PPARγ regulates M-CSF through NF-κB. RAW 264.7 cells were stimulated with LPS, which
resulted in a 21.6 ± 0.9-fold increase in M-CSF expression. LPS induced M-CSF expression
was reduced by 60 ± 26% when the NF-κB was inhibited with the proteasomal blocker.
Pioglitazone treatment also decreased LPS-stimulated M-CSF expression, by 68 ± 15% of the
LPS control (p < 0.05 vs LPS alone). The combination of both pioglitazone and NF-κB
inhibition resulted in 80 ± 25% reduction of M-CSF expression (p < 0.001 vs LPS). These data
suggest that PPARγ can regulate M-CSF induction through repression of NF-κB.
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FIGURE 7.
Pioglitazone inhibits LPS-mediated NF-κB activation. Whole-cell extracts were analyzed by
EMSA using a 32P-labeled oligonucleotide containing the κB consensus sequences and
analyzed on a 4% nondenaturing acrylamide gel. Specificity of the band was confirmed by
supershift analysis with p50 and p65 Abs and competition with cold oligonucleotide.
Representative image from four independent experiments is shown. Quantification using the
StormImager with ImageQuant analysis revealed that pretreatment with pioglitazone before
addition of LPS decreased NF-κB binding by 30.6 ± 6.9% (mean (SEM), p < 0.01 by Tukey's
test). US, Unstimulated; Pio, pioglitazone.
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FIGURE 8.
PPARγ inhibits LPS-induced NF-κB association with the M-CSF promoter. ChIP was
performed using BALB/c bone marrow-derived macrophages. After treatment with LPS (2
μg/ml), pioglitazone (Pio, 10 μg/ml), or GW9662 (GW, 10 mM), cell lysates were subjected
to immunoprecipitation with anti-PPARγ, anti-c-Rel, or anti-p65. Binding to the M-CSF
promoter was determined by real-time PCR. LPS stimulation resulted in c-Rel and p65 binding
to the NF-κB site upstream of the M-CSF promoter (B). Activation of PPARγ by pioglitazone
increased PPARγ association with the NF-κB response element, which was nearly eliminated
with NF-κB activation by LPS (A). Pioglitazone also resulted in PPARγ binding to the M-CSF
PPRE promoter region (C).
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FIGURE 9.
Model of PPARγ regulation of M-CSF transcription. Data from the ChIP and culture studies
were put together to develop a model of a working hypothesis in which PPARγ regulates M-
CSF through NF-κB. PPARγ inhibits association of NF-κB proteins with the promoter, an
effect that is enhanced in the presence of PPARγ activation. In the presence of NF-κB
activation, PPARγ binding to the promoter is down-regulated unless PPARγ is ligand-activated
by pioglitazone. In the absence of PPARγ, there is a potential constitutive production of M-
CSF through p65/c-Rel binding to NF-κB transcription site.
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Table I
Primers for TaqMan of M-CSF promoter
Murine M-CSF Promoter
mCSF-PPRE-F 5′-gtgaagtgaaatggggtgct-3′
mCSF-PPRE-R 5′-gtgattacgtttagaaccactgaa-3′
mCSF-NFκB-300F 5′-tccccattcaagtcctgttc-3′
mCSF-NFκB-300R 5′-tgtgcagcctcctcaaagta-3′
mCSF-NFκB-50F 5′-gggcctctggggtgtagtat-3′
mCSF-NFκB-50R 5′-ccgaggcaaactttcacttt-3′
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Table II
Cell counts in BAL
Model
Total Cell Count
(×104) Alveolar Macrophages (%) Lymphocytes (%) Neutrophils (%)
Wild type 1.34 ± 0.30 98 ± 9 2 ± 1.5 1 ± 1
GM-CSF KO 6.86 ± 4.93 70 ± 6 24 ± 3 5 ± 3
PPARγ 2.92 ± 1.67 72 ± 9 13 ± 2 13 ± 4
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